Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
Edward M Vital(University of Leeds), Raj Tummala(Hofstra University), Eric F. Morand(Novartis (Switzerland)), Ian N Bruce(University of Manchester), Joan T. Merrill(Oklahoma Medical Research Foundation), Rubana N. Kalyani(AstraZeneca (United States)), Richard Furie(Hofstra University), Gabriel Abreu(AstraZeneca (Finland)), Katie Streicher(AstraZeneca (United States)), Kenneth Kalunian(University of California, San Diego), Susan Manzi(Allegheny Health Network), Yoshiya Tanaka(University of Occupational and Environmental Health Japan)
Cited by 141
Related Papers
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis
|New England Journal of Medicine|2005|1.1k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
The immune cell landscape in kidneys of patients with lupus nephritis
|Nature Immunology|2019|840
Definition and initial validation of a Lupus Low Disease Activity State (LLDAS)
|Annals of the Rheumatic Diseases|2015|728